Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics.
A beneficial effect of the combination of quinupristin-dalfopristin and vancomycin was observed against two methicillin-resistant strains of Staphylococcus aureus harboring or not harboring the ermC gene, which codes for constitutive macrolide, lincosamide, and streptogramin B resistance. The beneficial effect was observed in time-kill studies, in which the drugs were used at inhibitory concentrations, and in a rabbit model of endocarditis, in which the combination was highly bactericidal and more active than monotherapies.
Institut National de la Santé et de la Recherche Médicale (EMI 9933), Faculté de Médecine Xavier Bichat, Paris.
Juliette
J
Pavie
Agnès
A
Lefort
Virginie
V
Zarrouk
Françoise
F
Chau
Louis
L
Garry
Roland
R
Leclercq
Bruno
B
Fantin
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D003470:Culture Media; D004351:Drug Resistance; D004359:Drug Therapy, Combination / Q000494:pharmacology* / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D055231:Lincosamides; D018942:Macrolides; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D013211:Staphylococcus aureus / Q000187:drug effects*; D025381:Streptogramin B / Q000494:pharmacology; D013997:Time Factors; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use*; D014769:Virginiamycin / Q000494:pharmacology* / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D003470:Culture Media; D055231:Lincosamides; D018942:Macrolides; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D025381:Streptogramin B; D014640:Vancomycin